Quantcast

Industry news that matters to you.  Learn more

Archives for April 2011

Biomagnetics, Los Alamos National Laboratory Agreement Produce Validated Assay for Tuberculosis Biomarker

Last week, Biomagnetics Diagnostics Corporation, a developer of revolutionary diagnostic systems and related technology for detecting HIV, hepatitis, tuberculosis, cholera and malaria, and other innovative technologies, announced that it has now completed a series of payments to Los Alamos National Laboratory (LANL) pursuant to the cooperative research and development agreement (CRADA) executed in 2010 between the two organizations.

Precision Therapeutics Announces New Tumor Profiling Product BioSpeciFx

Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFx®, will help further the personalization of cancer treatments. BioSpeciFx® is composed of carefully selected sets of well validated and clinically useful biomarker tests that identify critical molecular targets within a patient’s cell. By using the information generated by BioSpeciFx® in combination with Precision’s sophisticated drug response marker ChemoFx®, physicians may gain a more complete understanding of a patient’s tumor.

Protagen Counts on Scienion Technology

Protagen AG recently announced that Scienion AG will produce protein microarray batches for the clinical validation of the proprietary biomarker panels of Protagen. The batch sizes will comprise more than 1000 arrays.

Additionally, both companies plan to jointly evaluate new platforms for multiplex analytics and to co-develop novel approaches up to proof-of concept levels under a strategic partnership.

Plasma von Willebrand Factor a Biomarker for Risk of Adverse Events in Anticoagulated Atrial Fibrillation Patients

In patients with atrial fibrillation (AF) who were anticoagulated, plasma levels of von Willebrand factor (VWF) were found to be an independent risk factor for adverse events, including cardiovascular mortality and major bleeding. The study is published in the April 13th online edition of the Journal of the American College of Cardiology.

New Biomarker Test Enables Prognosis of Adverse Outcomes Following Acute Kidney Injury

Researchers at Cincinnati Children’s Hospital Medical Center report that a new biomarker-based diagnostic test is more effective than the current best practice for early detection of adverse outcomes after acute kidney injury (AKI). The multi-center study, to be published April 26 in the Journal of the American College of Cardiology (JACC), found that neutrophil gelatinase-associated lipocalin (NGAL) in urine or blood could detect early subclinical acute kidney injury and its adverse outcomes in critically ill patients. These same patients did not have diagnostic increases in serum creatinine, considered to be the gold standard for detecting AKI.